Hisamitsu Pharmaceutical Co (HTSUF) Price & Analysis

Compare

5 Followers

HTSUF Stock Chart & Stats

$28.79

-$0.66(0.00%)

At close: Apr 23 4:00 PM EDT

$28.79

-$0.66(0.00%)

Day’s Range― - ―

52-Week Range$24.75 - $34.59

Previous CloseN/A

Volume30.00

Average Volume (3M)0.00

Market Cap

$2.94B

Enterprise Value$323.55B

Total Cash (Recent Filing)$118.13B

Total Debt (Recent Filing)$2.65B

Price to Earnings (P/E)15.7

Beta0.23

Next Earnings

Apr 09, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.54%

Share Statistics

EPS (TTM)0.40

Shares Outstanding75,164,894

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.23

Price to Book (P/B)1.12

Price to Sales (P/S)1.99

P/FCF Ratio62.30

Enterprise Value/Market Cap109.97

Enterprise Value/Revenue2.09

Enterprise Value/Gross Profit3.53

Enterprise Value/Ebitda13.13

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross And EBITDA MarginsSustained high gross and healthy EBITDA margins indicate durable product-level economics and pricing power, likely driven by proprietary transdermal technology and product mix. Strong margins support R&D investment, margin resilience in pricing pressure, and long-term profitability stability.

Conservative Balance Sheet With High Equity RatioAn extremely high equity ratio and low leverage give the company financial flexibility to fund R&D, pursue partnerships, and weather sector cyclicality without heavy interest burdens. This conservative funding mix reduces solvency risk and preserves optionality for strategic investments.

Consistent Operating Cash Flow And Positive FCFReliable operating cash generation and persistent positive free cash flow underpin the firm's ability to self-fund product development, pay dividends or royalties, and sustain partnerships. Strong cash conversion supports long-term capital allocation without dependence on external financing.

Bears Say

Moderate Revenue Growth RateMid-single-digit revenue growth suggests slower top-line expansion relative to high-growth pharma peers. In a competitive specialty/generic market, modest organic growth means the company must rely on incremental product launches, geographic expansion, or partnerships to materially accelerate long-term revenue.

Growth In Total Liabilities Needs MonitoringAlthough leverage is low today, a trend of rising liabilities could erode the strong equity base and reduce financial flexibility over time. If liabilities accelerate faster than assets, the company may face tighter funding conditions or higher financing costs that could constrain strategic initiatives.

Net Profit Margin Has Room For ImprovementDespite high gross margins, a mid-teens net margin implies operating or SG&A pressures relative to best-in-class peers. Without improvements in operating efficiency or higher-margin product mix, net margin compression could limit free cash flow expansion and shareholder returns over the medium term.

Hisamitsu Pharmaceutical Co News

Taiyo Kosan Wins Control of Hisamitsu Pharmaceutical After Successful Tender Offer

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has issued an announcement. Taiyo Kosan Co., Inc. has successfully completed its...

2d ago

Hisamitsu Sets Record Date for Potential MBO-Linked Shareholder Meeting

The latest update is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical will set February 28,...

9d ago

TAIYO KOSAN Amends Tender Offer Filing for Hisamitsu Pharmaceutical After U.S. Antitrust Waiting Period

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has shared an announcement. Hisamitsu Pharmaceutical and its affiliate TAIYO KOSAN Co.,...

19d ago

Hisamitsu President’s Vehicle TAIYO KOSAN Launches Tender Offer to Boost Stake

The latest update is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). TAIYO KOSAN CO., INC. has launched...

2M ago

Hisamitsu Board Backs CEO-Led MBO and Recommends Shareholders Tender Stock

The latest announcement is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical’s board of directors has...

2M ago

Hisamitsu Posts Modest Sales Growth, Withdraws Forecast as MBO and Delisting Loom

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) has provided an announcement. Hisamitsu Pharmaceutical reported consolidated net sales of ¥114.5...

2M ago

Hisamitsu Pharmaceutical Scraps Year-End Dividend as Board Backs Privatization Tender Offer

Hisamitsu Pharmaceutical Co ( ($JP:4530) ) just unveiled an update. Hisamitsu Pharmaceutical has revised its dividend forecast for...

2M ago

Hisamitsu Withdraws Earnings Forecast Amid MBO-Linked Tender Offer and Planned Delisting

An update from Hisamitsu Pharmaceutical Co ( ($JP:4530) ) is now available. Hisamitsu Pharmaceutical has withdrawn its consolidated...

2M ago

Hisamitsu Pharmaceutical Completes Share Buyback Initiative

The latest update is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical Co., Inc. has completed...

3M ago

Hisamitsu Pharmaceutical Advances Share Buyback Strategy

The latest announcement is out from Hisamitsu Pharmaceutical Co ( ($JP:4530) ). Hisamitsu Pharmaceutical Co. has announced the...

4M ago

HTSUF FAQ

What was Hisamitsu Pharmaceutical Co Inc’s price range in the past 12 months?

Hisamitsu Pharmaceutical Co Inc lowest stock price was $24.75 and its highest was $34.59 in the past 12 months.

What is Hisamitsu Pharmaceutical Co Inc’s market cap?

Hisamitsu Pharmaceutical Co Inc’s market cap is $2.94B.

When is Hisamitsu Pharmaceutical Co Inc’s upcoming earnings report date?

Hisamitsu Pharmaceutical Co Inc’s upcoming earnings report date is Apr 09, 2026 which is in 46 days.

How were Hisamitsu Pharmaceutical Co Inc’s earnings last quarter?

Hisamitsu Pharmaceutical Co Inc released its earnings results on Jan 09, 2025. The company reported $0.402 earnings per share for the quarter, beating the consensus estimate of N/A by $0.402.

Is Hisamitsu Pharmaceutical Co Inc overvalued?

According to Wall Street analysts Hisamitsu Pharmaceutical Co Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Hisamitsu Pharmaceutical Co Inc pay dividends?

Hisamitsu Pharmaceutical Co Inc pays a Notavailable dividend of $0.416 which represents an annual dividend yield of 2.54%. See more information on Hisamitsu Pharmaceutical Co Inc dividends here

What is Hisamitsu Pharmaceutical Co Inc’s EPS estimate?

Hisamitsu Pharmaceutical Co Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hisamitsu Pharmaceutical Co Inc have?

Hisamitsu Pharmaceutical Co Inc has 75,164,894 shares outstanding.

What happened to Hisamitsu Pharmaceutical Co Inc’s price movement after its last earnings report?

Hisamitsu Pharmaceutical Co Inc reported an EPS of $0.402 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Hisamitsu Pharmaceutical Co Inc?

Currently, no hedge funds are holding shares in HTSUF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hisamitsu Pharmaceutical Co Inc

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.